30 closest matches · ranked by relevance
Colorectal Cancer With Non Resectable Hepatic Metastasis
Primary: Progression-free Survival Rate at 9 Months — 30; 26 Participants
Metastatic Colorectal Cancer
Primary: The Percentage of Patients Who Had a Curative (R0) Liver Metastasectomy Following Protocol Treatment, i.e., Metastatic Disease That Can be Completely Resected and/or…
Colorectal Cancer
Primary: Percentage of Participants Achieving Complete Resection (R0 Resection) — 30.0 percentage of participants
Colorectal Cancer Metastatic
Primary: Sorafenib Activity — 123 days
Colorectal Cancer
Primary: Complete Hepatic Response Rate at 3 Months — 79 percentage of participants
Colorectal Cancer
Primary: Overall Response Rate (ORR) — 75 percentage of evaluable participants
Colorectal Cancer · Metastatic Cancer
Primary: 2 Year Disease-free Survival . — 9 percentage of participants
Colorectal Cancer Metastatic
Primary: Overall Survival (OS) — 25.9; 25.0 months — p=0.43
Colorectal Cancer · Colorectal Carcinoma · Liver Metastases
Primary: Progression-Free Survival (PFS) at Any Site — 10.7; 10.2 Months — p=0.551
Colon Cancer With Metastases to the Liver
Primary: Tumor Response — 31; 16 participants
Rectal Cancer · Liver Metastases
Primary: Quality of Surgery for Primary Tumor — 2; 1; 15; 19 Participants — p=0.719
Colorectal Cancer
Primary: Percentage of Participants With Complete Resection or Residual (Microscopic or Macroscopic) Tumor — 48.7; 61.0; 33.3; 51.2 percentage of participants — p=0.2707
Metastatic Colorectal Cancer
Primary: Overall Rate of Response — 15 percentage of participants
Colorectal Cancer
Primary: Percentage of Participants With Conversion From Unresectable to Resectable Liver Metastases — 42.2 percentage of participants
Liver Metastases · Recurrent Colon Cancer · Recurrent Rectal Cancer
Primary: Number of Participants With at Least One Dose Limiting Toxicity — 0; 0; 1 participants with DLTs
Colorectal Cancer
Primary: Success of DEBIRI-M1 Procedure as a Measure of Feasibility (Percentage of Successful Treatments) — 100 percentage of successful treatments
Mucinous Adenocarcinoma of the Colon · Mucinous Adenocarcinoma of the Rectum · Signet Ring Adenocarcinoma of the Colon
Primary: Proportion of Patients Alive and Progression-free at 15 Months — .482 proportion of participants
Colorectal Cancer
Primary: Response Rate (Percentage of Participants With Partial or Complete Response) — 43 percentage of participants with response
Colorectal Cancer Metastatic
Primary: Progression Free Survival — 8.0; 7.2 Months — p=0.0013
Liver Metastases
Primary: Evaluation of Toxicity Related to Electrochemotherapy (Toxicity, Symptoms) — 0; 0; 0 events
Colon Adenocarcinoma · Rectal Adenocarcinoma · Recurrent Colon Carcinoma
Primary: To Examine the DLT — 200 mg
Colorectal Cancer Metastatic
Primary: Percentage of Participants With Adverse Events (AEs) — 100.00; 40.6; 21.1; 9.1 Percentage of participants
Metastatic Breast Cancer · Liver Metastases
Primary: Response Rate — 2; 13; 21; 1 Participants
Metastatic Colorectal Cancer
Primary: Participants With Recurrence Free Survival for Colorectal Cancer Participants With Resected Liver Metastases — 69; 47 percentage of participants
Colorectal Cancer · Neoplasm Metastasis
Primary: Response Rate for the Combination Treatment — 21 Participants
Metastatic Colorectal Cancer
Primary: Number of Subjects Who Experience Grade 3-5 Toxicity as a Measure of Safety and Tolerability. — 20 Participants
Colorectal Neoplasms · Metastases · Neoplasm
Primary: Percentage of Participants With an Overall Resonse — 8.2 percentage of participants
Colorectal Cancer
Primary: Overall Survival — 175.0; 169.0 Days — p=0.0021
Colorectal Cancer
Primary: Percentage of Participants Without Detectable Metastatic Disease After Secondary Resection Post Surgery — 84.6 Percentage of participants
Colorectal Cancer · Colorectal Carcinoma · Colorectal Adenocarcinoma
Primary: Number of Participants With Grade 1-5 Adverse Events — 4; 12; 4; 13 Participants